Skip to main content


Figure 1 | BMC Cancer

Figure 1

From: The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells

Figure 1

HNHA induced acetylation of histone H3 in RCC cells. Caki-1 and A-498 cells were treated for 24 h with 0.1, 1, 10, or 20 μM HNHA (A). Caki-1 and A-498 were treated with HNHA (15 μM) for 1, 6, 24, 48, or 72 h (B). Total proteins were isolated and histone H3 and α-tubulin acetylation was evaluated by Western blotting.

Back to article page